Publication:
CXCR4 targeted dendrimer for anti-cancer drug delivery and breast cancer cell migration inhibition

1
0

Issued Date

2017

Resource Type

Article

File Type

application/pdf

ISSN

9396411

DOI

10.1016/j.ejpb.2017.07.003

Other identifier(s)

2-s2.0-85023190732

Rights Holder(s)

มหาวิทยาลัยศรีนครินทรวิโรฒ

Bibliographic Citation

European Journal of Pharmaceutics and Biopharmaceutics. Vol 119, (2017), p.310-321

Suggested Citation

Chittasupho C., Anuchapreeda S., Sarisuta N. CXCR4 targeted dendrimer for anti-cancer drug delivery and breast cancer cell migration inhibition. European Journal of Pharmaceutics and Biopharmaceutics. Vol 119, (2017), p.310-321. doi:10.1016/j.ejpb.2017.07.003 Retrieved from: https://hdl.handle.net/20.500.14740/4065

Title

CXCR4 targeted dendrimer for anti-cancer drug delivery and breast cancer cell migration inhibition

Author(s)

Chittasupho C.
 Anuchapreeda S.
 Sarisuta N.

Abstract

CXCR4 and its ligand CXCL12 play a critical role in the metastasis of various types of cancer including breast cancer. Breast tumors preferentially metastasize to the lung, bones and distant lymph nodes, secreting high levels of CXCL12. We hypothesized that targeted inhibition of CXCR4 in breast cancer cells should suppress CXCR4-positive tumor cells toward secondary metastatic sites. In the present study, the efficacy of CXCR4 targeted dendrimers carrying DOX (LFC131-DOX-D4) on cellular binding, cytotoxicity, and migration of BT-549-Luc and T47D breast cancer cells was investigated. PAMAM dendrimers encapsulating DOX was surface functionalized with LFC131 peptide which recognized CXCR4 expressed on the surface of breast cancer cells. The LFC131-DOX-D4 bound to breast cancer cells resulting in significantly enhanced in vitro cellular toxicity as compared with non-targeted dendrimers. The LFC131-D4 exhibited remarkable reduced migration of BT-549-Luc breast cancer cells toward chemoattractant. This report demonstrated the potential utility of LFC131-dendrimer conjugates for breast cancer therapy and metastasis. © 2017 Elsevier B.V.

Subject(s)

Chemokine receptor
 Chemokine receptor CXCR4
 Dendrimer
 Doxorubicin
 LFC131 peptide
 Ligand
 Peptide
 Polyamidoamine
 Unclassified drug
 Antineoplastic agent
 Chemokine receptor CXCR4
 CXCR4 protein, human
 Dendrimer
 Doxorubicin
 PAMAM Starburst
 Stromal cell derived factor 1
 Article
 Binding affinity
 Breast cancer cell line
 BT-549-Luc cell line
 Cell migration
 Cell surface
 Cell viability assay
 Chemotaxis assay
 Competitive binding assay
 Conjugation
 Controlled study
 Cytotoxicity
 Drug delivery system
 Drug efficacy
 Drug receptor binding
 Drug release
 Drug uptake
 Human
 Human cell
 IC50
 In vitro study
 Incubation time
 Migration inhibition
 Nanoencapsulation
 Physical chemistry
 Protein expression
 T47D cell line
 Breast tumor
 Cell motion
 Drug delivery system
 Drug effects
 Female
 Metabolism
 Migration inhibition
 Procedures
 Signal transduction
 Tumor cell line
 Antineoplastic Agents
 Breast Neoplasms
 Cell Line, Tumor
 Cell Migration Inhibition
 Cell Movement
 Chemokine CXCL12
 Dendrimers
 Doxorubicin
 Drug Delivery Systems
 Female
 Humans
 Receptors, CXCR4
 Signal Transduction

View online Resources

Research Projects

Organizational Units

Journal Issue

URI

https://hdl.handle.net/20.500.14740/4065

Collections

Scopus: Year 1983-2021

Endorsement

Review

Supplemented By

Referenced By